Mats Blom - Auris Medical Director
Director
Mr. Mats Peter Blom is Director of the Company. Mats Blom is Senior Vice President and Chief Financial Officer of Zealand Pharma AS. Prior to joining Zealand, he served as CFO of Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mr. Blom has extensive managerial experience and has held CFO positions at Active Biotech AB and Anoto Group AB. Previously, he served as a management consultant at Gemini Consulting and Ernst Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona. since 2018.
| Age | 52 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 441 295 5950 |
| Web | http://www.aurismedical.com |
Auris Medical Management Efficiency
The company has return on total asset (ROA) of (21.99) % which means that it has lost $21.99 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (71.91) %, meaning that it created substantial loss on money invested by shareholders. Auris Medical's management efficiency ratios could be used to measure how well Auris Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 523.92 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Auris Medical Holding has a current ratio of 3.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Auris Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Auris Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Auris Medical Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Auris to invest in growth at high rates of return. When we think about Auris Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Rea | Verra Mobility Corp | 53 | |
| David Ho | Pentair PLC | 57 | |
| Mona Stephenson | Pentair PLC | 58 | |
| Michael Speetzen | Pentair PLC | 51 | |
| Hector Munoz | Grupo Aeroportuario del | 63 | |
| Roberto Sendra | Grupo Aeroportuario del | 91 | |
| Matthew Peltz | Pentair PLC | 35 | |
| Theodore Harris | Pentair PLC | 56 | |
| Agustin Rodriguez | Grupo Aeroportuario del | 57 | |
| Carol Davidson | Pentair PLC | 60 | |
| Jose Anton | Grupo Aeroportuario del | 47 | |
| Rasmus Christiansen | Grupo Aeroportuario del | 68 | |
| Edward Garden | Pentair PLC | 54 | |
| Luis Pardo | Grupo Aeroportuario del | 69 | |
| Michael Glenn | Pentair PLC | 62 | |
| Francisco Zambrano | Grupo Aeroportuario del | 64 | |
| Randall Bort | Verra Mobility Corp | 51 | |
| Carlos Coll | Grupo Aeroportuario del | 56 | |
| Ronald Merriman | Pentair PLC | 73 | |
| Guillermo Martinez | Grupo Aeroportuario del | 73 | |
| William Patton | Verra Mobility Corp | 70 | |
Management Performance
| Return On Equity | -71.91 | |||
| Return On Asset | -21.99 |
Auris Medical Holding Leadership Team
Elected by the shareholders, the Auris Medical's board of directors comprises two types of representatives: Auris Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auris. The board's role is to monitor Auris Medical's management team and ensure that shareholders' interests are well served. Auris Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auris Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cindy McGee, Head of Investor Relations and Corporate Communications | ||
| Hernan Levett, CFO | ||
| James Healy, Non-Executive Independent Vice Chairman of the Board | ||
| Bettina Stubinski, Chief Medical Officer | ||
| Thomas Meyer, Founder, Chairman, CEO and Managing Director | ||
| Calvin Roberts, Non-Executive Independent Director | ||
| Wolfgang Arnold, Board Member | ||
| Oliver Kubli, Board Member | ||
| Thomas Jung, Chief Development Officer | ||
| Andrea Braun, Head of Regulatory and Quality Affairs | ||
| Mats Blom, Director | ||
| Antoine Papiernik, Non-Executive Independent Director | ||
| Anne Zoller, General Counsel | ||
| Berndt Modig, Non-Executive Independent Director | ||
| Sven Zimmermann, CFO | ||
| Armando Anido, Non-Executive Independent Director | ||
| Alain Munoz, Director |
Auris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Auris Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -71.91 | |||
| Return On Asset | -21.99 | |||
| Current Valuation | 32.76 M | |||
| Shares Outstanding | 12.87 M | |||
| Shares Owned By Insiders | 5.45 % | |||
| Shares Owned By Institutions | 5.34 % | |||
| Number Of Shares Shorted | 362.97 K | |||
| Price To Earning | (1.05) X | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 224.60 X |
Pair Trading with Auris Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Auris Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Auris Medical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CarMax could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CarMax when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CarMax - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CarMax Inc to buy it.
The correlation of CarMax is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CarMax moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CarMax Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CarMax can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Auris Stock
If you are still planning to invest in Auris Medical Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Auris Medical's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |